Table 5.
Candidate Biomarker Ranking
| Protein | AUC | Specificity (%) at 90% Sensitivity | Sensitivity (%) at 90% Specificity | PTP+ (%) at 90% Sensitivity |
|---|---|---|---|---|
| Increaseda | ||||
| LDHA/LDH-M | 0.91 | 80 | 60 | 66 |
| FBP2 | 0.88 | 70 | 80 | 56 |
| ANP32A | 0.87 | 80 | 80 | 66 |
| FBP1 | 0.87 | 70 | 70 | 56 |
| QDPR | 0.87 | 60 | 70 | 49 |
| RIDA | 0.86 | 40 | 70 | 39 |
| FABP1 | 0.84 | 50 | 60 | 44 |
| ADH1B | 0.8 | 50 | 40 | 44 |
| ADH1A | 0.79 | 30 | 30 | 44 |
| MDH1 | 0.78 | 70 | 30 | 56 |
| IDH1 | 0.76 | 70 | 30 | 56 |
| ASS1 | 0.74 | 50 | 50 | 44 |
| HIST1H4A | 0.69 | 70 | 0 | 56 |
| Decreasedb | ||||
| APOC2 | 0.88 | 70 | 60 | 56 |
| FVII | 0.87 | 70 | 70 | 56 |
| PSMD11 | 0.8 | 40 | 50 | 39 |
| Reference markers | ||||
| MELD | 0.47 | 20 | 13 | 31 |
| ALT | 0.39 | 0 | 10 | 0 |
PTP calculation is based on 30% pretest probability of death.
Abbreviations: PTP+, positive posttest probability.
Increased ≥4-fold in ALF survivors versus controls and ≥4-fold further in nonsurvivors versus survivors.
Decreased ≥4-fold in ALF survivors versus controls and ≥4-fold further in nonsurvivors versus survivors.